Lymphokine gene therapy for cancer

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

The plethora of recombinant lymphokines that have recently become available has led to renewed hope for an immunotherapeutic solution to cancer. Many lymphokines, either singly or in combination, have already shown promise in animal trials and in preliminary human trials. Systemic lymphokine toxicity has been the major constraint on this type of therapy, often precluding the use of doses sufficient to induce tumour regression. To realize the therapeutic potential of recombinant lymphokines against cancer, alternative modes of delivery are needed which maximally stimulate local anti-tumour responses whilst causing minimal systemic toxicity. In this article, Stephen Russell proposes that tumour cell targeted lymphokine gene therapy would optimize lymphokine delivery. Some of the practical difficulties likely to be encountered with such an approach are also discussed.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalImmunology Today
Volume11
Issue numberC
DOIs
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Lymphokine gene therapy for cancer'. Together they form a unique fingerprint.

  • Cite this